source
- Evaxion scraps solid tumor vaccine to focus on Duke-partnered brain cancer candidateEvaxion has scrapped a next-gen solid tumor vaccine in order to channel resources to a candidate specifically targeting brain cancer.Fierce Biotech · 9h ago↗ source
- Silence Therapeutics' Phase 2 trial shows strong results for divesiran in polycythemia vera, shares jump 30%Silence Therapeutics reported that its nucleic‑acid drug divesiran achieved a 69% placebo‑adjusted response rate in a Phase 2 study of polycythemia vera patients. Safety was reported as clean, with…